PTD-DBM

A cell-permeable peptide designed to activate the Wnt/beta-catenin signaling pathway by disrupting the CXXC5-Dishevelled interaction. This pathway is critical for hair follicle neogenesis and cycling. PTD-DBM has shown remarkable results in preclinical models, stimulating new hair follicle formation from stem cells — a mechanism distinct from existing hair loss treatments that merely preserve existing follicles.

• Disrupts CXXC5-Dishevelled protein-protein interaction
• Releases suppression of Wnt/beta-catenin signaling in hair follicle stem cells
• Promotes conversion of resting telogen follicles to active anagen phase
• Stimulates de novo hair follicle formation from dermal stem cells
• PTD domain enables cell membrane penetration without additional carriers

• Active skin cancer or precancerous lesions (Wnt pathway involvement in tumorigenesis)
• Pregnancy or breastfeeding
• Inflammatory scalp conditions (untreated psoriasis, severe dermatitis)

Store at 2–8°C (36–46°F) for up to 3 months. For long-term storage, keep at -20°C (-4°F). Once reconstituted, refrigerate and use within 14 days. Highly sensitive to freeze-thaw cycles.

Published in 2017 by researchers at Yonsei University (South Korea) in the Journal of Investigative Dermatology, PTD-DBM demonstrated new hair follicle formation in mice — a result not achieved by any currently approved hair loss treatment. The study showed that topical application to wound sites produced fully functional hair follicles from stem cells. The mechanism targets CXXC5, a negative regulator of Wnt signaling that is overexpressed in balding scalp. While extremely promising, the peptide remains in preclinical development with human trials pending.